Last reviewed · How we verify
Pioglitazone HCl Tablets 45 mg
At a glance
| Generic name | Pioglitazone HCl Tablets 45 mg |
|---|---|
| Sponsor | Mylan Pharmaceuticals Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hypoglycaemia
- Headache
- Diarrhoea
- Nasopharyngitis
- Upper respiratory tract infection
- Dyspepsia
- Hypertension
- Urinary tract infection
- Pain in extremity
- Bronchitis
- Gastritis
- Edema peripheral
Key clinical trials
- Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss (PHASE4)
- Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants (PHASE4)
- Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus (PHASE2)
- Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg (PHASE1)
- Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg (PHASE1)
- Pharmacogenomics of Thiazolidinediones (NA)
- Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus (PHASE2)
- Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone HCl Tablets 45 mg CI brief — competitive landscape report
- Pioglitazone HCl Tablets 45 mg updates RSS · CI watch RSS
- Mylan Pharmaceuticals Inc portfolio CI